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Diabetes is a critical chronic disease that has exerted considerable health and economic influence on the United 
States population. Although diabetes has imposed a considerable economic burden on health systems 
worldwide, the incremental economic effect of certain diabetic complications has not been extensively studied 
and quantified. The aim of this study is to quantitatively define the economic burden resulting from the presence 
of diabetic eye and kidney complications. 
 
Methods 
Data was analyzed from the Medical Expenditure Panel Survey (MEPS) 2012-2016 to provide an updated 
evaluation on the association between several forms of annual health expenditures and the presence of diabetic 
kidney and eye complications. Demographic qualities of the U.S. diabetic population were analyzed by 
presenting weighted percentages according to complication status.  Total expenditures and several component 
sources were analyzed by presenting mean and standard error of spending. A multivariable regression was used 
to evaluate effects from comorbidities and complications on total, out of pocket, and prescription-based annual 
spending. Out of pocket and prescription spending were chosen as supplement models to characterize the 
individual patient burden. 
 
Results 
Diabetic complications were more common among the elderly, Non-Hispanic Black and Hispanic individuals, 
and those with related comorbid diseases. Increased spending due to the presence of these diabetic 
complications was generally observed in trends of total annual expenditures as well as several component 
sources of spending. Total annual spending increased by 74% among those with kidney complications, while 
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the presence of eye complications was associated with a 33% increase.  Diabetic kidney complications were 
associated with a 54% increase in annual out of pocket spending, while eye complications led to a 15% 
increase. Annual prescription spending was elevated by 66% in those with kidney complications, and increased 
by 36% among patients with diabetic eye complications. 
 
Conclusions 
This analysis clearly illustrates that the economic difficulty patients with diabetic complications requires 
targeted interventions. It is also demonstrated that these measures are likely to benefit those who are older and 
possess other related chronic comorbidities. The presence of diabetic kidney and eye complications generally 
led to increases among many components of health spending, often with the most considerable elevation among 
those with both conditions. More specifically, notable increases in out of pocket and prescription expenditures 
suggest that alleviation of the personal financial difficulty may be most critical when implementing reform to 

















 Diabetes is a chronic condition affecting approximately 30.3 million individuals in the United States. 
This influence comprises an estimated 9.4% of the total population, with an estimated 7 million total hospital 
discharges in the United States reported among adults with a diabetes diagnosis [1]. Diabetes can also lead to 
serious medical complications such as cardiovascular disease, diabetic nephropathy and diabetic retinopathy. 
The risk of complications is often dependent on the management of associated risk factors, with the most 
critical being smoking, obesity, physical inactivity, high blood pressure, high cholesterol, and high blood 
glucose [1]. In 2015, diabetes was also the seventh leading cause of death in the United States [1]. 
With the high overall prevalence of diabetes and the subsequent risk for serious complications, the 
potential economic burden of this disease is substantial. In the United States, the overall economic cost of 
diagnosed diabetes was estimated to be 245 billion dollars [1].  The nature of diabetic expenditures has been 
evaluated extensively in previous literature. It has been previously determined that the spending of individuals 
with type 2 diabetes is approximately 2.3 times greater than those without diabetes and these differences are 
also associated with worsened quality of life among these patients [2]. Another study examined the magnitude 
of lifetime costs associated with diabetes, and found that individuals with diabetes spend considerably more 
over their lifetime even with an overall decreased life expectancy [3]. Compared to those without diabetes, 
diabetics possessed a discounted excess lifetime spending of $124,600 when diagnosed at age 40, and $91,200 
when diagnosed at age 50 [3]. Much of this increase in spending was attributed to prescription medications and 
inpatient hospital care [3]. Diabetic individuals not only are susceptible to increased economic burden from 
direct costs, there is an additional influence from indirect health costs such as absenteeism, decreased work 
productivity, unemployment from disability, and productivity loss resulting from early mortality [4]. The range 
of effects from diabetes are shown to greatly influence the broader national burden, ultimately influencing all 
portions of society through alterations in insurance premiums and changes in quality of life [4]. 
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Several examples from the literature have previously addressed critical economic effects in vulnerable 
subpopulations. One such investigation examined the range of diabetic expenditures present in patients with 
cardiovascular disease, specifically, myocardial infarction and ischemic stroke. It was found that these patients 
experience a considerable increase in expenditures as a result of diabetes [6]. It was subsequently indicated that 
improved management of diabetes in these individuals, when better controlling factors such as blood pressure 
and cholesterol, will likely also decrease the critical financial burden from stroke and myocardial infarction. 
This study also suggests that utilization of cost-effective diabetic medications may also be important in these at-
risk groups [6]. Furthermore, another study examined the reasons for increasing costs of diabetic medications 
and identified methods of controlling this price elevation [7].  
Although these investigations have provided useful insights, it is clear there has not been substantial 
focus on the subpopulation of diabetics with more severe complications resulting from disease progression or 
ineffective care. Therefore, the following analysis represents a more specific and unique cost examination. This 
evaluation is centered on the economic burden of diabetes severity, represented by the presence of eye or kidney 
complications that commonly result from progression of diabetes. This will provide a more nuanced evaluation 
of diabetes expenditures by comparing patterns of costs between diabetic individuals with and without these 
complications. Overall, this study will provide useful insight about whether interventions to improve treatment 
or limit severity of more advanced diabetic complications can facilitate broader economic benefits among this 




The Medical Expenditure Panel Survey (MEPS) is a collection of comprehensive surveys and questionnaires 
used to acquire self-reported health information from families, medical professionals, and employers in the 
United States. MEPS is sponsored by the Agency for Healthcare Research and Quality (AHRQ), as part of the 
United States Department of Health and Human Services.  The MEPS is composed primarily of two 
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components, including the household component and the insurance component. The panel design utilizes 
multiple rounds of interviewing to account for a two-year period. The survey also acquires quantitative 
information regarding broader utilization and costs associated with health services and insurance procedures. 
The MEPS database also provides further differentiation of these expenditures by component sources of 
payment. Furthermore, the Diabetes Care Survey (DCS) is an additional questionnaire administered through 
MEPS since 2000 in order to collect further information from individuals who previously reported having a 
diabetes diagnosis. The DCS provides two individual questions that inquire about the presence of diabetic 
kidney or eye complications: “Has your diabetes caused problems with your kidneys?” and “Has your diabetes 
caused problems with your eyes that needed to be treated by an ophthalmologist?” The sample involved in this 
evaluation included U.S. adults above the age of 18 who have been clinically diagnosed with diabetes. The 
analysis specifically utilized data pooled from the years of 2012 to 2016 to increase sample size and evaluate 
the most recent trends available. This data was subsequently utilized to collectively examine the association 
between annual health related expenditures among diabetics and the presence of kidney and eye related 
complications. The complex sampling design and corresponding weight variables were considered and utilized 




Variables of Interest 
The key dependent variable in this analysis is health care expenditures for individuals diagnosed with diabetes 
in the United States. This measure specifically accounts for the overall sum of direct payments for health care of 
the corresponding survey year [8]. This value includes out of pocket care payments, as well as payments by 
private insurance, Medicaid, Medicare, and other component expenditure sources. Furthermore, payments not 
considered in this estimate include those for over the counter drugs and other indirect charges that are not 
related to particular health events [8]. These measures of expenditures incorporate information from both the 
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MEPS Household and Medical Provider Components. The comprehensive definition included office-based 
physician visits, hospital inpatient events, prescribed medication, dental and vision care, medical equipment, 
and home health services. The MEPS provides an aggregate measure that includes spending resulting from all 
applicable sources, as well as more specific variables representing each of the component payment sources. [8]. 
The key independent variable in this analysis is the presence of specific diabetic complications, including 
kidney complications and eye complications. As previously described, identification of these complications was 
based on two individual self-reported questions from the supplement Diabetes Care Survey. 
 
Controlled Covariates 
Controlled covariates in this quantitative evaluation were obtained from corresponding portions of the MEPS 
self-reported questionnaire. Race/ethnicity was categorized into Hispanic, Non-Hispanic White, Non-Hispanic 
Black, and other races. Age was categorized into 18-44, 45-64, and 65 and older. Health insurance status was 
categorized into private insurance, public insurance, and no insurance. Marital status was categorized into 
married, not married (widowed, separated, or divorced), and never married. Comorbid conditions that are 
commonly associated with diabetes were also evaluated in this analysis. These additional illnesses included 
coronary heart disease, myocardial infarction, stroke, hypertension, and high cholesterol. Identification of these 
comorbid disease conditions were based on binary responses to corresponding MEPS survey questions. Survey 
information was further categorized by individual year, including 2012, 2013, 2014, 2015, and 2016. 
 
Analyses 
Diabetic complication status was categorized into the four following groups: no kidney or eye complications, 
kidney complications only, eye complications only, and both kidney and eye complications. Demographic 
characteristics of the final sample of diabetic adults were analyzed by presenting weighted percentages for each 
respective complication category.  Total expenditures as well as several component payments sources were 
examined by presenting the mean spending value and standard error. This portion of the analysis similarly 
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utilized the previous categorization of diabetic complication status. Both analyses accounted for population 
weights in the sample of individuals with diabetes. Furthermore, a multivariable regression was performed to 
examine effect of patient characteristics, particularly the presence of comorbidities and complications, on 
spending. Three unique regression models were used to analyze total health expenditures, out of pocket 
expenditures, and prescription expenditures. Out of pocket and prescription spending were analyzed to better 
illustrate the personal economic burden experienced by patients. Logarithmic transformation of the respective 
expenditure outcome was utilized to better construct a normal distribution among this data. Logarithmic 
transformation was chosen as a framework of analysis to allow for utilization of population weights in the 




Table 1 illustrates the demographic characteristics of the final sample of diabetic individuals in the United 
States, according to complication status (none, kidney only, eye only, both kidney and eye). The total sample 
included 8,436 individuals, which represented a weighted total sample of 15,175,124 individuals in the United 
States. The majority of this sample, comprising 6,163 individuals (73.1%) did not have kidney or eye 
complications. Kidney complications alone were present in 472 individuals (5.6%), while eye complications 
alone were present in 1,289 individuals (15.3%). Both kidney and eye complications occurred in 512 
individuals (6.1%) from this sample. Individuals with complications were more likely to be older. Groups with 
complications displayed greater population percentages of Non-Hispanic Black and Hispanic individuals. 
Individuals with complications were less likely to possess private insurance and more likely to have a form of 
public health insurance. Patients with complications were also more likely to possess other related 








Weighted demographics of U.S. Adults with diabetes according to complication status (unweighted n=8,436, 





























level p < 
0.05*) 
Age Category       
18-44 11.2 12.1 8.0 9.1 7.9 0.03* 
45-64 44.3 45.1 38.4 43.8 41.4 0.14 
65+ 44.5 42.8 53.6 47.1 50.7 <0.001* 
Race/ethnicity 
Category 
      
Non-Hispanic 
White 
61.9 63.1 72.9 52.3 57.8 <0.001* 
Non-Hispanic 
Black 
15.2 14.6 12.7 18.9 17.4 0.001* 
Hispanic 15.0 14.5 8.9 19.6 18.1 <0.001* 
Other Race 7.8 7.8 5.5 9.3 6.8 0.17 
Gender Category       
Male 48.6 49.1 51.7 44.4 48.6 0.11 
Marital Status 
Category 
      
Married 56.4 58.0 51.9 51.0 53.0 0.006* 
Not Married 32.4 30.8 36.4 36.5 38.6 0.001* 
Never Married 11.2 11.2 11.6 12.5 8.3 0.25 
Insurance 
Category 
      
Private Insurance 58.4 61.9 50.8 49.6 41.4 <0.001* 
Public Insurance 35.4 32.0 43.3 44.4 51.0 <0.001* 




      
Coronary Heart 
Disease 
18.2 15.5 27.6 21.7 36.7 <0.001* 
Heart Attack 13.7 11.7 20.6 16.9 26.1 <0.001* 
Stroke 12.6 10.3 21.3 16.4 25.6 <0.001* 
Hypertension 77.6 75.3 87.2 79.9 93.5 <0.001* 
High Cholesterol 74.8 73.1 81.9 77.3 83.8 <0.001* 
Survey Year 
Category 
      
2012 11.7  11.3 11.5 14.3 11.3  
2013 24.4 23.8 26.7 26.7 24.6  
2014 25.7 25.7 25.7 25.9 25.1  
2015 13.0 13.3 11.4 10.8 15.3  





Table 2 displays mean health spending for total expenditures, as well as several payment sources and utilization 
categories. Compared to the spending of individuals without complications, total expenditures were increased in 
the presence of either of the diabetic complications, and considerably higher when both complications were 
present. This trend among complication categories was observed for payments by Medicaid and Medicare, with 
these associations being statistically significant. With regards to payments by private insurance, the presence of 
either complication did not strongly affect the mean expenditure value, although the presence of both 
complications did lead to a noticeable increase in payment. In the case of out of pocket spending, the most 
considerable increase in expenditure occurred among patients with kidney complications alone. Patterns among 
office-based expenditures and prescription expenditures were similar in that the presence of either complication 
significantly increased spending and the most substantial effect was observed among individuals with both 
complications. With regards to outpatient and emergency room expenditures, the most considerable increases in 





Table 2  
Mean (standard error) of annual health expenditures for aggregate and component payment sources according to 

































































































Table 3 illustrates the association between various patient characteristic and the change in total health spending 
for a given year. Total spending was significantly associated with increasing patient age. Furthermore, Non-
Hispanic Blacks, Hispanics, and other races possessed significantly decreased spending compared to Non-
Hispanic Whites. Males spent significantly less in total than females, while marital status did not significantly 
impact total expenditures. Individuals with either private or public insurance spent significantly more than those 
without health insurance. The presence of related comorbidities led to increased total expenditures and the 
impact of coronary heart disease, stroke, and hypertension were most considerable and statistically significant. 
These represented percent changes of 35%, 57% and 21% respectively. The presence of kidney complications 








Multivariable adjusted regression model using log transformation of annual total health expenditures, 







(standard error) in 




p < 0.05 *) 
Age Category    
18-44 (reference) - - - 
45-64 0.33 39 (7.0) <0.001* 
65+ 0.43 53 (7.3) <0.001* 
Race/ethnicity Category    
Non-Hispanic White 
(reference) 
- - - 
Non-Hispanic Black -0.37 -31 (6.1) <0.001* 
Hispanic -0.40 -33 (6.2) <0.001* 
Other Race -0.38 -31 (8.1) <0.001* 
Gender Category    
Female (reference) - - - 
Male -0.16 -15 (4.5) <0.001* 
Marital Status Category    
Never Married (reference) - - - 
Not Married -0.063 -6.0 (7.0) 0.39 
Married -0.058 -6 (7.2) 0.37 
Insurance Category    
No Insurance (reference) - - - 
Private Insurance 1.01 174 (8.8) <0.001* 
Public Insurance 1.09 196 (9.5) <0.001* 
Comorbidity Category     
Coronary Heart Disease 0.30 35 (5.7) <0.001* 
Heart Attack 0.077 8.0 (5.7) 0.17 
Stroke 0.45 57 (6.5) <0.001* 
Hypertension 0.19 21 (5.5) <0.001* 
High Cholesterol 0.10 11 (5.2) 0.05 
Diabetes Complication 
Category 
   
Kidney-related 
Complications 
0.55 74 (7.6) <0.001* 








Table 4 demonstrates the associations between diabetic patient characteristics and annual out of pocket 
spending on health services. Out of pocket expenditures were significantly elevated with increasing age, and 
significantly decreased among other races when compared to Non-Hispanic Whites. Males spent significantly 
less than females, while married individuals spent more than those never married. Individuals with public forms 
of health insurance spent significantly less out of pocket compared to those without insurance. Significant 
increases in out of pocket spending occurred in the presence of coronary heart disease, stroke, and hypertension. 
These conditions were associated with 16%, 16%, and 12% increases in out of pocket spending, respectively. 
The presence of diabetic kidney complications was associated with a 54% increase in out of pocket 















(standard error) in 




p < 0.05 *) 
Age Category    
18-44 (reference) - - - 
45-64 0.41 51 (8.0) <0.001* 
65+ 0.62 87 (8.1) <0.001* 
Race/ethnicity Category    
Non-Hispanic White 
(reference) 
-  - 
Non-Hispanic Black -0.58 -44 (5.6) <0.001* 
Hispanic -0.73 -52 (6.8) <0.001* 
Other Race -0.60 -45 (9.1) <0.001* 
Gender Category    
Female (reference) -  - 
Male -0.13 -12 (4.4) 0.003* 
Marital Status Category    
Never Married (reference) -  - 
Not Married 0.089 9.3 (8.2) 0.26 
Married 0.23 26.3 (8.7) 0.01* 
Insurance Category    
No Insurance (reference) -  - 
Private Insurance -0.091 -8.7 (8.4) 0.26 
Public Insurance -0.92 -60 (8.6) <0.001* 
Comorbidity Category     
Coronary Heart Disease 0.14 16 (6.9) 0.03* 
Heart Attack -0.13 -12 (7.5) 0.08 
Stroke 0.15 16 (6.8) 0.03* 
Hypertension 0.11 12 (5.4) 0.03* 
High Cholesterol 0.066 6.8 (5.9) 0.25 
Diabetes Complication 
Category 
   
Kidney-related 
Complications 
0.43 54 (8.0) <0.001* 








Table 5 illustrates the association between diabetic patient characteristics and annual prescription spending in 
this population. Increasing patient age was associated with significantly increased spending. Additionally, 
prescription spending was significant decreased among Non-Hispanic Blacks, Hispanics, and other races when 
compared to Non-Hispanic Whites. Males spent significantly less than females, while marital status did not 
have a considerable impact on prescription expenditures. The presence of private or public health insurance led 
to a significant increased in prescription spending. The comorbidities of coronary heart disease, stroke, 
hypertension and high cholesterol were associated with 33%, 37%, 34%, and 21% changes in prescription 
spending, respectively. These effects were also statistically significant. The presence of kidney complications 
was associated with a statistically significant 66% increase in prescription spending, while diabetic eye 






















p < 0.05 *) 
Age Category    
18-44 (reference) - - - 
45-64 0.32 37 (9.4) <0.001* 
65+ 0.29 33 (10.1) 0.003* 
Race/ethnicity Category    
Non-Hispanic White 
(reference) 
- - - 
Non-Hispanic Black -0.46 -37 (6.5) <0.001* 
Hispanic -0.50 -39 (7.2) <0.001* 
Other Race -0.33 -28 (9.0) <0.001* 
Gender Category    
Female (reference)    
Male -0.12 -11 (5.8) 0.04* 
Marital Status Category    
Never Married (reference)    
Not Married -0.086 -8.3 (8.5) 0.29 
Married -0.10 -9.6 (9.1) 0.25 
Insurance Category    
No Insurance (reference)    
Private Insurance 0.89 143 (9.9) <0.001 
Public Insurance 1.02 177 (10.6) <0.001 
Comorbidity Category     
Coronary Heart Disease 0.28 33 (7.3) <0.001* 
Heart Attack -0.084 -8.1 (8.6) 0.31 
Stroke 0.32 37 (7.0) <0.001* 
Hypertension 0.30 34 (7.0) <0.001* 
High Cholesterol 0.19 21 (6.2) 0.002* 
Diabetes Complication 
Category 
   
Kidney-related 
Complications 
0.51 66 (8.9) <0.001* 













 Kidney complications affected 5.6% of diabetic individuals in this sample, while eye complications 
affected 15.3% of individuals. Both kidney and eye complications were present in 6.1% of the sample. 
Accordingly, a majority of this sample not have diabetic kidney or eye complications. Complications were more 
frequent in older segments of this sample, as well as among Non-Hispanic Black and Hispanic individuals. 
Diabetic kidney and eye complications were also more common among individuals with public health insurance 
and among those with related cardiovascular comorbidities. Total health expenditures were elevated when either 
complication was present, while the presence of both conditions led to a more substantial increase in spending. 
Increased spending due to the presence of these diabetic complications was generally observed across many 
component sources of spending, including payments by Medicaid and Medicare, of out of pocket spending, 
office-based expenditures, prescription expenditures, outpatient spending, and emergency room expenditures. 
Total annual spending, out of pocket spending, and prescription spending in this diabetic sample was 
significantly increased due to older patient age and decreased among Non-Hispanic Blacks, Hispanics, and 
other races. Males spent significantly less among all sources compared to females. Individuals with private or 
public insurance spent significantly more in total and on prescriptions, but possessed lower out of pocket 
expenditures. Elevations among all spending sources resulted from comorbidities of coronary heart disease, 
stroke, and hypertension. Total spending experienced a 74% increase among those with kidney complications, 
while the presence of eye complications led to a 33% increase.  Diabetic kidney complications led to a 54% 
increase in out of pocket expenditures, while diabetic eye complications were associated with a 15% increase. 
Prescription spending increased by 66% in the presence of kidney complications, and was elevated by 36% in 
those with diabetic eye complications. 
There are many potential factors that can lead to the results observed in this analysis. When the presence 
of self-reported kidney complications can signal the progression of underlying diabetic kidney disease, the 
associated difficulties with the management of this condition is likely responsible for much of this increased 
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spending. Providing the necessary, regular treatment for patients with diabetic kidney disease is an expensive 
process. Patients with this condition often require comprehensive clinical management of measures such as 
blood pressure, glucose, and lipids [9]. These individuals may also require lifestyle modifications such as an 
exercise regimen, smoking cessation, and weight reduction [9]. Unfortunately, attaining consistent control of 
such an extensive range of physiological factors is often difficult to achieve, and can lead to worsened health 
outcomes in this vulnerable population. Nonadherence to treatment can result from difficulties in self-
regulation, variation in physician recommendations, and problems regarding emotional well-being [9]. For these 
reasons, it can be clearly demonstrated that the presence of more severe kidney complications easily results in a 
considerable economic burden for the individual patient. 
In a similar manner, it can be shown that the presence of diabetic eye complications can feasibly result 
in an increased economic burden for this at-risk population. Such complications may include considerable 
vision impairment from the progression of diabetic nephropathy, as well as the presence of cataracts, glaucoma, 
and macular degeneration [10]. Management of these conditions requires consistent ophthalmologic screening 
and corresponding management of clinical risk factors. More severe conditions may also necessitate regular 
forms of surgical intervention [10]. Improving awareness and education regarding optimal treatment of diabetic 
eye disease represents another substantial barrier to patient adherence and positive wellbeing [10]. As a result, 
poor or inconsistent management of these conditions may similarly lead to an overwhelming economic burden 
for these individuals. 
Ultimately, the findings from this analysis indicate the importance of interventions to alleviate economic 
difficulties among patients in the United States with diabetic complications. Expanding access to health 
insurance and the provision of discounted community health services may help to counteract the considerable 
amount of out of pocket spending in this population. Additionally, methods to address prescription-based 
expenditures, such as modification of copay amounts and broader utilization of generic pharmaceuticals, may 
also be beneficial to combat this critical aspect of the economic burden among diabetic individuals. 
Furthermore, characterizing the individual experience of this patient population by analyzing out of pocket and 
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prescription expenditures highlights how efforts to minimize diabetic severity can provide tangible benefits. In 
this manner, targeting more thorough and regular methods treatment among those at-risk for developing 
complications can help to prevent subsequent financial difficulty. In a similar way, managing the progression 
and severity of complications among diabetics who already possess these conditions can help to mitigate the 
economic difficulties that stem from issues of nonadherence and inconsistent regimens of care. 
The strengths of this analysis include the more narrow and meaningful scope attained by focusing on the 
specific burden for diabetic individuals with kidney or eye complications. Additionally, expanding the notion of 
health expenditures to include more specific component sources of spending provides a more nuanced outlook 
on the nature of these economic patterns. Use of regression analysis also allows for a direct and quantitative 
comparison among patients in this vulnerable population. Potential limitations of this analysis include the 
inability to specifically identify differences between individuals with Type 1 and Type 2 diabetes using 
information from MEPS, since variation between these populations may affect the quantification of spending 
among all individuals with diabetes. Additionally, the original categorization of complication status was not 
maintained in subsequent regression analyses, which only facilitated a comparison between individuals with and 
without each respective condition. Furthermore, there does not always exist a clear differentiation among all 
separate component sources of health spending. For example, the spending on prescription medications may 
include expenditures that naturally fall under the out of pocket categorization. Another possible limitation 
involves the potential bias that results from relying on self-reported measure regarding factors involving health 










While a majority of diabetics in the United States may not specifically possess kidney or eye complications, this 
study demonstrates that the extent of the economic burden that results for patients with these conditions 
justifiably necessitates more targeted interventions. It is also shown that individuals in the at-risk population for 
which these measures would be beneficial is likely to be older and possess other related chronic comorbidities. 
The presence of these complications generally led to increases among many components of health spending, 
with some facets experiencing more substantial elevation among those with both conditions. Notable increases 
in out of pocket and prescription expenditures suggest that alleviation of the personal aspects of financial 
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